journal
MENU ▼
Read by QxMD icon Read
search

Haematologica

journal
https://read.qxmd.com/read/30765477/sdf1%C3%AE-induced-chemotaxis-of-jak2-v617f-positive-cells-is-dependent-on-bruton-s-tyrosine-kinase-and-its-downstream-targets-pi3k-akt-plc%C3%AE-1-and-rhoa
#1
Subbaiah Chary Nimmagadda, Stephanie Frey, Peter Müller, Denise Wolleschak, Söenke Weinert, Ulrich Keller, Bärbel Edelmann, Thomas Fischer
No abstract text is available yet for this article.
February 14, 2019: Haematologica
https://read.qxmd.com/read/30765476/post-transplant-outcome-of-ovarian-tissue-cryopreserved-after-chemotherapy-in-hematological-malignancies
#2
Catherine Poirot, Anne Fortin, Nathalie Dhédin, Pauline Brice, Gérard Socié, Jean-Marc Lacorte, Jean-Paul Akakpo, Catherine Genestie, Jean-Paul Vernant, Thierry Leblanc, Jean Gabarre, Alain Delmer, Yasmina Badachi, Véronique Drouineaud, Céline Chalas, Sophie Egels, Philippe Touraine, Marc Dommergues, Géraldine Lebègue, Jean-Philippe Wolf, Frédérique Capron, Gilles Lefebvre, Nicolas Boissel
No abstract text is available yet for this article.
February 14, 2019: Haematologica
https://read.qxmd.com/read/30765475/diet-and-gender-influence-survival-of-transgenic-berkley-sickle-cell-mice
#3
Om B Jahagirdar, Aditya M Mittal, Waogwende L Song-Naba, Ritu Jha, Stacy B Kiven, Susan T Thompson, John E Connett, Kalpna Gupta
No abstract text is available yet for this article.
February 14, 2019: Haematologica
https://read.qxmd.com/read/30765474/quantitative-dynamic-18f-fdg-pet-ct-before-autologous-stem-cell-transplantation-predicts-survival-in-multiple-myeloma
#4
Christos Sachpekidis, Maximilian Merz, Annette Kopp-Schneider, Anna Jauch, Marc-Steffen Raab, Sandra Sauer, Jens Hillengass, Hartmut Goldschmidt, Antonia Dimitrakopoulou-Strauss
No abstract text is available yet for this article.
February 14, 2019: Haematologica
https://read.qxmd.com/read/30765473/endothelialised-vascular-flow-models-for-blood-transfusion-research
#5
Monica S Y Ng, Jacky Y Suen, John-Paul Tung, John F Fraser
No abstract text is available yet for this article.
February 14, 2019: Haematologica
https://read.qxmd.com/read/30765472/venetoclax-penetrates-in-cerebrospinal-fluid-and-may-be-effective-in-cll-with-central-nervous-system-involvement
#6
Gianluigi Reda, Ramona Cassin, Gabriela Dovrtelova, Cristina Matteo, Juri Giannotta, Maurizio D'Incalci, Agostino Cortelezzi, Massimo Zucchetti
No abstract text is available yet for this article.
February 14, 2019: Haematologica
https://read.qxmd.com/read/30765471/dimeric-ferrochelatase-bridges-abcb7-and-abcb10-homodimers-in-an-architecturally-defined-molecular-complex-required-for-heme-biosynthesis
#7
Nunziata Maio, Ki Soon Kim, Gregory Holmes-Hampton, Anamika Singh, Tracey A Rouault
Loss-of-function mutations in the ABC transporter of the inner mitochondrial membrane, ABCB7, cause X-linked sideroblastic anemia with ataxia, a phenotype that remains largely unexplained by the proposed role of ABCB7 in exporting a special sulfur species for use in cytosolic iron-sulfur (Fe-S) cluster biogenesis. Here, we generated inducible ABCB7-knockdown cell lines to examine the time-dependent consequences of loss of ABCB7. We found that knockdown of ABCB7 led to significant loss of mitochondrial Fe-S proteins, which preceded the development of milder defects in cytosolic Fe-S enzymes...
February 14, 2019: Haematologica
https://read.qxmd.com/read/30765470/durable-remissions-in-tcf3-hlf-positive-acute-lymphoblastic-leukemia-with-blinatumomab-and-stem-cell-transplantation
#8
Brice Mouttet, Luciana Vinti, Philip Ancliff, Nicole Bodmer, Benoît Brethon, Gunnar Cario, Christiane Chen-Santel, Sarah Elitzur, Volkan Hazar, Joachim Kunz, Anja Möricke, Jerry Stein, Ajay Vora, Yöntem Yaman, Martin Schrappe, Sema Sanak, André Baruchel, Franco Locatelli, Arend von Stackelberg, Martin Stanulla, Jean-Pierre Bourquin
No abstract text is available yet for this article.
February 14, 2019: Haematologica
https://read.qxmd.com/read/30733275/rapid-growth-is-a-dominant-predictor-of-hepcidin-suppression-and-declining-ferritin-in-gambian-infants
#9
Andrew E Armitage, Schadrac C Agbla, Modupeh Betts, Ebrima A Sise, Momodou W Jallow, Ellen Sambou, Bakary Darboe, Archibald Worwui, George M Weinstock, Martin Antonio, Sant-Rayn Pasricha, Andrew M Prentice, Hal Drakesmith, Momodou K Darboe, Brenda Anna Kwambana-Adams
Iron deficiency and iron deficiency anemia are highly prevalent in low-income countries, especially among young children. Hepcidin is the major regulator of systemic iron homeostasis. It controls dietary iron absorption, dictates whether absorbed iron is made available in circulation for erythropoiesis and other iron-demanding processes, and predicts response to oral iron supplementation. Understanding how hepcidin is itself regulated is therefore important, especially in young children. We investigated how changes in iron-related parameters, inflammation and infection status, season and growth influenced plasma hepcidin and ferritin concentrations during infancy using longitudinal data from two birth-cohorts of rural Gambian infants (N=114 and N=193)...
February 7, 2019: Haematologica
https://read.qxmd.com/read/30733274/serendipity-decitabine-monotherapy-induced-complete-molecular-response-in-a-77-year-old-patient-with-acute-promyelocytic-leukemia
#10
Ramzi Abboud, Se Young Han, Eric J Duncavage, Amanda F Cashen, Cara Lunn Shirai, John S Welch, John F DiPersio, Camille N Abboud
No abstract text is available yet for this article.
February 7, 2019: Haematologica
https://read.qxmd.com/read/30733273/the-novel-cd19-targeting-antibody-drug-conjugate-hub4-dgn462-shows-improved-anti-tumor-activity-than-sar3419-in-cd19-positive-lymphoma-and-leukemia-models
#11
Stuart W Hicks, Chiara Tarantelli, Alan Wilhem, Eugenio Gaudio, Min Li, Alberto J Arribas, Filippo Spriano, Roberta Bordone, Luciano Cascione, Katharine C Lai, Qifeng Qiu, Monica Taborelli, Davide Rossi, Georg Stüssi, Emanuele Zucca, Anastasios Stathis, Callum M Sloss, Francesco Bertoni
Antibody-drug conjugates (ADCs) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADCs targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development. Here, we present huB4-DGN462, a novel ADC based on the SAR3419 anti-CD19 antibody linked via sulfo-SPDB to the potent DNA-alkylating agent DGN462. huB4-DGN462 had improved in vitro anti-proliferative and cytotoxic activity compared to SAR3419 across multiple B-cell lymphoma and human acute lymphoblastic leukemia cell lines...
February 7, 2019: Haematologica
https://read.qxmd.com/read/30733272/burkitt-like-lymphoma-with-11q-aberration-a-germinal-center-derived-lymphoma-genetically-unrelated-to-burkitt-lymphoma
#12
Blanca Gonzalez-Farre, Joan Enric Ramis-Zaldivar, Julia Salmeron-Villalobos, Olga Balagué, Verónica Celis, Jaime Verdu-Amoros, Ferran Nadeu, Constantino Sábado, Antonio Ferrández, Marta Garrido, Federico García-Bragado, María Dolores de la Maya, José Manuel Vagace, Carlos Manuel Panizo, Itziar Astigarraga, Mara Andrés, Elaine S Jaffe, Elias Campo, Itziar Salaverria
Burkitt-like lymphoma with 11q aberration is characterized by pathological features and gene expression profile resembling Burkitt lymphoma but lack MYC rearrangement and carries an 11q-arm aberration with proximal gains and telomeric losses. Whether these lymphomas are a distinct category or a particular variant of other recognized entities is controversial. To improve the understanding of Burkitt-like lymphoma with 11q aberration we have performed an analysis of copy number alterations and targeted sequencing of a large panel of B-cell lymphoma related genes in 11 cases...
February 7, 2019: Haematologica
https://read.qxmd.com/read/30733271/a-phase-ii-study-of-guadecitabine-in-higher-risk-myelodysplastic-syndrome-and-low-blast-count-acute-myeloid-leukemia-after-azacitidine-failure
#13
Marie Sébert, Aline Renneville, Cécile Bally, Pierre Peterlin, Odile Beyne-Rauzy, Laurence Legros, Marie-Pierre Gourin, Laurence Sanhes, Eric Wattel, Emmanuel Gyan, Sophie Park, Aspasia Stamatoullas, Anne Banos, Kamel Laribi, Simone Jueliger, Luke Bevan, Fatiha Chermat, Rosa Sapena, Olivier Nibourel, Cendrine Chaffaut, Sylvie Chevret, Claude Preudhomme, Lionel Adès, Pierre Fenaux
High-risk myelodysplastic syndrome/acute myeloid leukemia patients have a very poor survival after azacitidine failure. Guadecitabine (SGI-110) is a novel subcutaneous hypomethylating agent, which results in extended decitabine exposure. This multicenter phase II study evaluated the efficacy and safety of guadecitabine in high-risk myelodysplastic syndrome and low blast count acute myeloid leukemia patients refractory or relapsing after azacitidine. We included 56 patients with a median age of 75 years (IQR 69-76)...
February 7, 2019: Haematologica
https://read.qxmd.com/read/30733270/once-weekly-versus-twice-weekly-carfilzomib-in-patients-with-newly-diagnosed-multiple-myeloma-a-pooled-analysis-of-two-phase-1-2-studies
#14
Sara Bringhen, Roberto Mina, Maria Teresa Petrucci, Gianluca Gaidano, Stelvio Ballanti, Pellegrino Musto, Massimo Offidani, Stefano Spada, Giulia Benevolo, Elena Ponticelli, Piero Galieni, Michele Cavo, Tommaso Caravita di Toritto, Francesco Di Raimondo, Vittorio Montefusco, Antonio Palumbo, Mario Boccadoro, Alessandra Larocca
Twice-weekly carfilzomib is approved at 27 and 56 mg/m2 to treat relapsed multiple myeloma patients. In the phase 3 study A.R.R.O.W., once-weekly 70 mg/m2 carfilzomib prolonged the median progression-free survival of relapsed multiple myeloma patients in comparison with twice-weekly 27 mg/m2 carfilzomib, without adding significant toxicity. Data were pooled from two phase 1/2 studies of newly diagnosed multiple myeloma patients who received nine induction cycles of carfilzomib (either 70 mg/m2 once-weekly or 36 mg/m2 twice-weekly), cyclophosphamide and dexamethasone, followed by carfilzomib maintenance...
February 7, 2019: Haematologica
https://read.qxmd.com/read/30733269/long-term-outcome-after-allogeneic-hematopoietic-cell-transplantation-for-myelofibrosis
#15
Marie Robin, Liesbeth C de Wreede, Christine Wolschke, Johannes Schetelig, Dirk-Jan Eikema, Maria Teresa Van Lint, Nina Simone Knelange, Dietrich Beelen, Arne Brecht, Dietger Niederwieser, Antonin Vitek, Wolfgang Bethge, Renate Arnold, Jürgen Finke, Liisa Volin, Ibrahim Yakoub-Agha, Arnon Nagler, Xavier Poiré, Hermann Einsele, Patrice Chevallier, Ernst Holler, Per Ljungman, Stephen Robinson, Aleksandar Radujkovic, Donal McLornan, Yves Chalandon, Nicolaus Kröger
Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first 2 years and hence we aimed to analyze the outcome of 2-year disease-free survivors. 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated...
February 7, 2019: Haematologica
https://read.qxmd.com/read/30733268/clonal-evolution-in-myeloma-the-impact-of-maintenance-lenalidomide-and-depth-of-response-on-the-genetics-and-sub-clonal-structure-of-relapsed-disease-in-uniformly-treated-newly-diagnosed-patients
#16
John R Jones, Niels Weinhold, Cody Ashby, Brian A Walker, Christopher Wardell, Charlotte Pawlyn, Leo Rasche, Lorenzo Melchor, David A Cairns, Walter M Gregory, David Johnson, Dil B Begum, Sidra Ellis, Amy L Sherborne, Gordon Cook, Martin F Kaiser, Mark T Drayson, Roger G Owen, Graham H Jackson, Faith E Davies, Mel Greaves, Gareth J Morgan
The emergence of treatment resistant sub-clones is a key feature of relapse in multiple myeloma. Therapeutic attempts to extend remission and prevent relapse include the maximisation of response and use of maintenance therapy. We used whole exome sequencing to study the genetics of paired presentation and relapse samples from 56 newly diagnosed patients, following induction therapy, randomised to receive either lenalidomide maintenance or observation as part of the Myeloma XI trial. Patients included were considered high risk, relapsing within 30 months of maintenance randomisation...
February 7, 2019: Haematologica
https://read.qxmd.com/read/30733267/anti-apoptotic-bcl2l2-increases-megakaryocyte-proplatelet-formation-in-cultures-of-human-cord-blood
#17
Seema Bhatlekar, Indranil Basak, Leonard C Edelstein, Robert A Campbell, Cory R Lindsey, Joseph E Italiano, Andrew S Weyrich, Jesse W Rowley, Matthew T Rondina, Martha Sola-Visner, Paul F Bray
Apoptosis is a recognized limitation for generating large numbers of megakaryocytes in culture. The responsible apoptosis genes have been rigorously studied in vivo in mice, but are poorly characterized in human culture systems. As CD34+ cells isolated from human umbilical vein cord blood were differentiated into megakaryocytes in culture, two distinct cell populations were identified by flow cytometric forward and side scatter: larger size, lower granularity and smaller size, higher granularity. The larger size, lower granularity cells were CD41aHighCD42aHighphosphatidylserineLow, had an electron microscopic morphology similar to mature bone marrow megakaryocytes, developed proplatelets, and displayed a signaling response to platelet agonists...
February 7, 2019: Haematologica
https://read.qxmd.com/read/30733266/reactivation-of-hepatitis-b-infection-in-patients-with-haematological-disorders
#18
Bo Wang, Ghulam Mufti, Kosh Agarwal
Hepatitis B reactivation is the reappearance or rise of hepatitis B virus (HBV) DNA in patients with past or chronic HBV infection, usually occurring in the context of immunosuppression. HBV reactivation has been most commonly reported in patients with haematological disorders, with potentially serious and life-threatening consequences. In this review, we discuss the basis and presentation of HBV reactivation, risk factors in terms of the host, the virus and the immunosuppression regimen, focusing on specific treatments relevant to haematology patients...
February 7, 2019: Haematologica
https://read.qxmd.com/read/30733265/platelet-glycoprotein-vi-and-c-type-lectin-like-receptor-2-deficiency-accelerates-wound-healing-by-impairing-vascular-integrity-in-mice
#19
Surasak Wichaiyo, Sian Lax, Samantha J Montague, Zhi Li, Beata Grygielska, Jeremy A Pike, Elizabeth J Haining, Alexander Brill, Steve P Watson, Julie Rayes
Platelets promote wound healing by forming a vascular plug and by secreting growth factors and cytokines. Glycoprotein (GP)VI and C-type lectin-like receptor (CLEC)-2 signal through a (hem)-immunoreceptor tyrosine-based activation motif, which induce platelet activation. GPVI and CLEC-2 support vascular integrity during inflammation in the skin through regulation of leukocyte migration and function, and by sealing sites of vascular damage. In this study, we have investigated the role of impaired vascular integrity due to GPVI and/or CLEC-2 deficiency in wound repair using a full-thickness excisional skin wound model in mice...
February 7, 2019: Haematologica
https://read.qxmd.com/read/30733264/fecal-microbiota-transplantation-before-or-after-allogeneic-hematopoietic-transplantation-in-patients-with-hematological-malignancies-carrying-multidrug-resistance-bacteria
#20
Giorgia Battipaglia, Florent Malard, Marie Therése Rubio, Annalisa Ruggeri, Anne Claire Mamez, Eolia Brissot, Federica Giannotti, Remy Dulery, Anne Christine Joly, Minh Tam Baylatry, Marie Jeanne Kossman, Jaques Tankovic, Laurent Beaugerie, Harry Sokol, Mohamad Mohty
Fecal microbiota transplantation is an effective treatment in recurrent Clostridium difficile infection. Promising results to eradicate multidrug-resistant bacteria have also been reported with this procedure, but there are safety concerns in immunocompromised patients. We report results in 10 adult patients colonized with multidrug-resistant bacteria, undergoing fecal microbiota transplantation before (n=4) or after (n=6) allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Stools were obtained from healthy related or unrelated donors...
February 7, 2019: Haematologica
journal
journal
24858
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"